Skip Nav Destination
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Issue Archive
April 4 2013
In this Issue
Table of Contents
Inside Blood
Blood Work
Plenary Paper
Perspectives
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
Francesco Rodeghiero,Marc Michel,Terry Gernsheimer,Marco Ruggeri,Victor Blanchette,James B. Bussel,Douglas B. Cines,Nichola Cooper,Bertrand Godeau,Andreas Greinacher,Paul Imbach,Mehdi Khellaf,Robert J. Klaassen,Thomas Kühne,Howard Liebman,Maria Gabriella Mazzucconi,Adrian Newland,Ingrid Pabinger,Alberto Tosetto,Roberto Stasi
Review Article
Clinical Trials and Observations
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
Clinical Trials & Observations
Sarah Bertoli,Emilie Bérard,Françoise Huguet,Anne Huynh,Suzanne Tavitian,François Vergez,Sophie Dobbelstein,Nicole Dastugue,Véronique Mansat-De Mas,Eric Delabesse,Eliane Duchayne,Cécile Demur,Audrey Sarry,Valérie Lauwers-Cances,Guy Laurent,Michel Attal,Christian Récher
Hematopoiesis and Stem Cells
Immunobiology
Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack
Jamie A. Lopez,Olivia Susanto,Misty R. Jenkins,Natalya Lukoyanova,Vivien R. Sutton,Ruby H. P. Law,Angus Johnston,Catherina H. Bird,Phillip I. Bird,James C. Whisstock,Joseph A. Trapani,Helen R. Saibil,Ilia Voskoboinik
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56bright subset
Emily M. Mace,Amy P. Hsu,Linda Monaco-Shawver,George Makedonas,Joshua B. Rosen,Lesia Dropulic,Jeffrey I. Cohen,Eugene P. Frenkel,John C. Bagwell,John L. Sullivan,Christine A. Biron,Christine Spalding,Christa S. Zerbe,Gulbu Uzel,Steven M. Holland,Jordan S. Orange
NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs
Vivien Béziat,Lisa L. Liu,Jenny-Ann Malmberg,Martin A. Ivarsson,Ebba Sohlberg,Andreas T. Björklund,Christelle Retière,Eva Sverremark-Ekström,James Traherne,Per Ljungman,Marie Schaffer,David A. Price,John Trowsdale,Jakob Michaëlsson,Hans-Gustaf Ljunggren,Karl-Johan Malmberg
Lymphoid Neoplasia
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia
Karen A. Urtishak,Alena Y. Z. Edwards,Li-San Wang,Amanda Hudome,Blaine W. Robinson,Jeffrey S. Barrett,Kajia Cao,Lori Cory,Jonni S. Moore,Andrew D. Bantly,Qian-Chun Yu,I-Ming L. Chen,Susan R. Atlas,Cheryl L. Willman,Mondira Kundu,Andrew J. Carroll,Nyla A. Heerema,Meenakshi Devidas,Joanne M. Hilden,ZoAnn E. Dreyer,Stephen P. Hunger,Gregory H. Reaman,Carolyn A. Felix
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
Shimin Hu,Zijun Y. Xu-Monette,Aarthi Balasubramanyam,Ganiraju C. Manyam,Carlo Visco,Alexander Tzankov,Wei-min Liu,Roberto N. Miranda,Li Zhang,Santiago Montes-Moreno,Karen Dybkær,April Chiu,Attilio Orazi,Youli Zu,Govind Bhagat,Kristy L. Richards,Eric D. Hsi,William W. L. Choi,J. Han van Krieken,Qin Huang,Jooryung Huh,Weiyun Ai,Maurilio Ponzoni,Andrés J. M. Ferreri,Xiaoying Zhao,Jane N. Winter,Mingzhi Zhang,Ling Li,Michael B. Møller,Miguel A. Piris,Yong Li,Ronald S. Go,Lin Wu,L. Jeffrey Medeiros,Ken H. Young
Myeloid Neoplasia
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
Brief Report
Marta Pratcorona,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Salut Brunet,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Josep Nomdedéu,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Josep Maria Ribera,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Mar Tormo,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Rafael Duarte,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Lourdes Escoda,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Ramon Guàrdia,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,M. Paz Queipo de Llano,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Olga Salamero,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Joan Bargay,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Carmen Pedro,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Josep Maria Martí,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Montserrat Torrebadell,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Marina Díaz-Beyá,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Mireia Camós,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Dolors Colomer,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Montserrat Hoyos,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Jorge Sierra,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas,Jordi Esteve,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Brief Report
Pratap Neelakantan,Gareth Gerrard,Claire Lucas,Dragana Milojkovic,Philippa May,Lihui Wang,Christos Paliompeis,Marco Bua,Alistair Reid,Katayoun Rezvani,Stephen O'Brien,Richard Clark,John Goldman,David Marin
Platelets and Thrombopoiesis
Platelets lacking PIP5KIγ have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion
Yanfeng Wang,Liang Zhao,Aae Suzuki,Lurong Lian,Sang H. Min,Ziqian Wang,Rustem I. Litvinov,Timothy J. Stalker,Tadayuki Yago,Arkadiusz G. Klopocki,David W. Schmidtke,Helen Yin,John K. Choi,Rodger P. McEver,John W. Weisel,John H. Hartwig,Charles S. Abrams
Red Cells, Iron, and Erythropoiesis
Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria
Lucia Gargiulo,Maria Papaioannou,Michela Sica,Giulia Talini,Aristeidis Chaidos,Barbara Richichi,Andrei V. Nikolaev,Cristina Nativi,Mark Layton,Josu de la Fuente,Irene Roberts,Lucio Luzzatto,Rosario Notaro,Anastasios Karadimitris
Thrombosis and Hemostasis
Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease
Jiong-Wei Wang,Eveline A. M. Bouwens,Maria Carolina Pintao,Jan Voorberg,Huma Safdar,Karine M. Valentijn,Hetty C. de Boer,Koen Mertens,Pieter H. Reitsma,Jeroen Eikenboom
Transplantation
Vascular Biology
Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody
Mai Yoshikawa,Yohei Mukai,Yoshiaki Okada,Yuki Tsumori,Shin-ichi Tsunoda,Yasuo Tsutsumi,William C. Aird,Yasuo Yoshioka,Naoki Okada,Takefumi Doi,Shinsaku Nakagawa
Errata
-
Cover Image
Cover Image
![issue cover]()
Blood outgrowth endothelial cells (BOEC) were isolated and cultured from patients with type 1 or 2 Von Willebrand disease (VWD) or from healthy controls. The cells were activated with phorbol 12-myristate 13-acetate (PMA) which, in BOEC from healthy individuals, stimulates release of Von Willebrand factor (VWF) from its intracellular storage in Weibel-Palade bodies (WPB). Displayed are BOEC from a type 1 VWD patient, which lack WPB and therefore do not release VWF upon PMA; thus VWF strings are missing from the cell surface. Isolation of BOEC from VWD patients allowed for the first time the investigation of cellular phenotypes of patients with different VWD subtypes, which were found to correlate with the clinical phenotypes. BOEC are stained for VWF (green) and nuclei (blue). See the article by Starke et al on page 2773.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
